BioCryst Pharmaceuticals Q2 2025 Earnings Preview

12 hours ago 1

BioCryst Pharmaceuticals (NASDAQ:BCRX) is scheduled to announce Q2 earnings results on Monday, August 4th, before market open.
The consensus EPS Estimate is $0.03 (+150.0% Y/Y) and the consensus Revenue Estimate is $149.82M (+37.0% Y/Y).
Over the last 2 years, BCRX

Recommended For You